97 related articles for article (PubMed ID: 7574362)
1. Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
Lagattolla NR; Stacey MC; Burnand KG; Gaffney PG
Ann Cardiol Angeiol (Paris); 1995; 44(6):299-303. PubMed ID: 7574362
[TBL] [Abstract][Full Text] [Related]
2. Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Stacey MC; Burnand KG; Mahmoud-Alexandroni M; Gaffney PJ; Bhogal BS
Br J Surg; 1993 May; 80(5):596-9. PubMed ID: 8518896
[TBL] [Abstract][Full Text] [Related]
3. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
4. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
Darras V; Thienpont M; Stump DC; Collen D
Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay.
Kuo BS; Bjornsson TD
Anal Biochem; 1993 Feb; 209(1):70-8. PubMed ID: 8465964
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
[TBL] [Abstract][Full Text] [Related]
8. Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Rogers AA; Burnett S; Lindholm C; Bjellerup M; Christensen OB; Zederfeldt B; Peschen M; Chen WY
Vasa; 1999 May; 28(2):101-5. PubMed ID: 10409920
[TBL] [Abstract][Full Text] [Related]
9. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts.
De Petro G; Copeta A; Barlati S
Exp Cell Res; 1994 Jul; 213(1):286-94. PubMed ID: 8020601
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
12. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor.
Mars WM; Kim TH; Stolz DB; Liu ML; Michalopoulos GK
Cancer Res; 1996 Jun; 56(12):2837-43. PubMed ID: 8665523
[TBL] [Abstract][Full Text] [Related]
13. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.
Mwaura B; Mahendran B; Hynes N; Defreitas D; Avalos G; Adegbola T; Adham M; Connolly CE; Sultan S
Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):306-10. PubMed ID: 16169261
[TBL] [Abstract][Full Text] [Related]
14. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
15. Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study.
Stacey MC; Mata SD
Cardiovasc Surg; 2000 Aug; 8(5):381-5. PubMed ID: 10959063
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
17. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix.
Grøndahl-Hansen J; Kirkeby LT; Ralfkiaer E; Kristensen P; Lund LR; Danø K
Am J Pathol; 1989 Oct; 135(4):631-6. PubMed ID: 2508479
[TBL] [Abstract][Full Text] [Related]
20. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
